October 23, 2026  -  Fertility, Medical Device

Overture Life Launches Robot-Assisted Fertilization Technology in the US

Overture

Overture Life has made its robot-assisted fertilization technology, ICSI.A, commercially available in fertility labs throughout the US following completion of its FDA establishment registration and device listing.

ICSI.A is a class II medical device and robotic intracytoplasmic sperm injection (ICSI) workstation that assists embryologists during IVF procedures by positioning the injection needle and holding pipette.

“ICSI is one of the most technically demanding procedures in an IVF laboratory, where even small movements require tremendous precision,” said Luis Guzmán, PhD, Lab Director at CERAS. “Robot-assisted micromanipulation represents an important step forward because it gives embryologists greater control over how instruments are positioned and guided while keeping the critical decisions and injection procedure in their hands.” 

Backed by GV and Khosla Ventures, Overture Life develops assisted reproductive technology and was the first company to achieve live births from both robotic fertilization and robotic egg freezing. With ICSI.A now commercially available, the company aims to automate every step of the IVF process, including embryo freezing, assessment, fertilization, and other processes in development.

“With ICSI.A entering the U.S. market, clinics can adopt that work without replacing the laboratories they’ve already built,” said Hans Gangeskar, Co-Founder and CEO of Overture Life. “We think the next generation of embryologists will consider robotic precision at the microscope as fundamental as the microscope itself.”

Femtech Insider
Femtech Insider